Video

Dr. Phillips Discusses Novel Treatment Regimen in MCL

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses a novel treatment regimen for patients with mantle cell lymphoma.

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses a novel treatment regimen for patients with mantle cell lymphoma (MCL).

In a study presented at the 2018 ASH Annual Meeting, all patients received the standard dose of bendamustine and rituximab (BR; Rituxan) at 80 mg/m2 and 375 mg/m2, respectively. Bendamustine was given on days 1 and 2 and rituximab was given on day 2 of the treatment cycle. The second-generation BTK inhibitor acalabrutinib (Calquence) was given at the standard dose of 100 mg daily.

The cohort of treatment-naïve patients were given the option of transitioning to rituximab maintenance therapy after initial treatment. Acalabrutinib also continued to be dosed daily, says Phillips. Relapsed/refractory patients were transitioned from initial treatment of BR plus acalabrutinib to acalabrutinib as a single agent.

At the meeting, investigators reported an overall response rate (ORR) of 94% in the treatment-naïve cohort, and a complete response (CR) rate of 72%. Median duration of response (DOR) and median progression-free survival had not been reached (NR) in this cohort. The relapsed/refractory (R/R) cohort saw an ORR of 80% and a CR rate of 65% with the combination. The median DOR for the R/R cohort was 15 months (95% CI, 12.2-NR), while median PFS was 16.6 months (95% CI, 14.2-NR).

Related Videos
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD